rabeprazole has been researched along with Otitis Media with Effusion in 2 studies
Rabeprazole: A 4-(3-methoxypropoxy)-3-methylpyridinyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.
Otitis Media with Effusion: Inflammation of the middle ear with a clear pale yellow-colored transudate.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sone, M | 2 |
| Kato, T | 1 |
| Suzuki, Y | 1 |
| Arao, H | 1 |
| Sugiyama, K | 1 |
| Ishida, K | 1 |
| Izawa, K | 1 |
| Takasu, A | 1 |
| Nakashima, T | 2 |
| Yamamuro, Y | 1 |
| Hayashi, H | 1 |
| Yanagi, E | 1 |
| Niwa, Y | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Clinical Trial of Proton Pump Inhibitors to Treat Children With Chronic Otitis Media With Effusion[NCT00546117] | 16 participants (Actual) | Interventional | 2007-10-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00546117)
Timeframe: 2 months
| Intervention | participants (Number) |
|---|---|
| Prevacid | 1 |
| Placebo | 3 |
(NCT00546117)
Timeframe: 2 months
| Intervention | participants (Number) |
|---|---|
| Prevacid | 1 |
| Placebo | 0 |
Spectral gradient acoustic reflectometry is a noninvasive, non-audible acoustic wave used to help detect middle ear fluid. The manufacturer recommends interpretation of the angle result as: <49°, high risk of middle ear effusion (level 5); 49-59°, moderate-high risk (level 4); 60-69°, moderate risk (level 3); 70-95°, low-moderate risk (level 2) and >95°, low risk (level 1). (NCT00546117)
Timeframe: 2 months
| Intervention | level of risk (Mean) |
|---|---|
| Lansoprazole (Prevacid) | 2.5 |
| Placebo | 3.5 |
Questions regarding reflux symptoms, created and evaluated by Nelson et al, Prevalence of symptoms of gastroesophageal reflux during childhood: a pediatric practice-based survey, Arch Pediatr Adolesc Med 2000;154;150-154. This study used the GER3-9P version for children aged 3-9 years. Results are reported as number reporting at least one specific symptom in the past week, maximum 7 symptoms. (NCT00546117)
Timeframe: 2 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Lansoprazole (Prevacid) | 0 |
| Placebo | 0 |
"Tympanometry of both ears, coded by Jerger classification (Type A, normal; type B, flat; Type C; negative pressure).~This is a standard test of middle ear status as performed by audiologists. Please refer to the reference for more information: Kileny & Zwolan, Diagnostic Audiology, chapter 133, Cummings Otolaryngology-Head and Neck Surgery, Elsevier/Saunders, 2015." (NCT00546117)
Timeframe: 2 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Lansoprazole (Prevacid) | 0 |
| Placebo | 0 |
2 other studies available for rabeprazole and Otitis Media with Effusion
| Article | Year |
|---|---|
Relevance and characteristics of gastroesophageal reflux in adult patients with otitis media with effusion.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Bilirubi | 2011 |
Prediction of gastroesophageal reflux in otitis media with effusion in adults.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Ear, Mid | 2007 |